(Q54179293)

English

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years

scientific article published on March 1, 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years (English)

reason for preferred rank

most precise value

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

6

object named as

R N Jones

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

4

object named as

P C Fuchs

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

E. Hugh Gerlach

5

object named as

E H Gerlach

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

author name string

S. A. Marshall

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

K. E. Aldridge

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

S. D. Allen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7648836

15 July 2024

publication date

1 March 1995

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

full work available at URL

https://api.elsevier.com/content/article/PII:0732889395000197?httpAccept=text/xml

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

https://api.elsevier.com/content/article/PII:0732889395000197?httpAccept=text/plain

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

21

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

153-168

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

1

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam

3

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers

4

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.

5

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

6

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System

7

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Characterization of beta-lactamases

8

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

9

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

10

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

11

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles

12

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

13

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

14

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli

15

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

More extended-spectrum beta-lactamases

16

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

17

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

18

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results

19

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.

20

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria

22

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam

23

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

24

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Tazobactam prevention of emergence of resistance.

29

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections

30

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone

31

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobact

33

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection

35

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

37

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid

38

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

39

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Identifiers

10.1016/0732-8893(95)00019-7

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54179293&oldid=2204700238"